Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 3/20 | 0.54 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.51 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4869903 | 0.88 | AVPR2 (0.58) | PRMT5WDR77POLBTP53LMNA | |
| SCHEMBL4863318 | 0.88 | AVPR2 (0.58) | PRMT5WDR77POLBTP53LMNA | |
| SCHEMBL4869628 | 0.86 | NAMPT (0.58) | PRMT5WDR77SMN1; SMN2POLBTSHR | |
| SCHEMBL4871945 | 0.85 | AVPR2 (0.58) | PRMT5WDR77SMN1; SMN2POLBTSHR | |
| SCHEMBL4865660 | 0.84 | TP53 (0.49) | PRMT5WDR77SMN1; SMN2POLBTSHR | |
| SCHEMBL4869809 | 0.84 | AVPR2 (0.58) | PRMT5WDR77SMN1; SMN2POLBTSHR | |
| SCHEMBL4864926 | 0.84 | TP53 (0.53) | PRMT5WDR77SMN1; SMN2POLBRECQL | |
| SCHEMBL4868750 | 0.84 | PRMT5 (0.53) | PRMT5WDR77SMN1; SMN2POLBTSHR | |
| SCHEMBL4865042 | 0.83 | TSHR (0.64) | PRMT5WDR77SMN1; SMN2POLBTSHR | |
| SCHEMBL17117363 | 0.82 | NAMPT (0.60) | PRMT5WDR77SMN1; SMN2POLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7368444-B2 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-06 | — | — | US | disclosed |
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1475368-A1 | N-CARBAMOYL NITROGEN-CONTAINING FUSED RING COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2004-11-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101600-A1 | N-carbamoyl nitrogen-containing fused ring compounds and drugs containing these compounds as the active ingredient | CNR1, CNR2, NPSR1 | PRMT5 752/4885WDR77 3899/4885SMN1; SMN2 2595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.